Aplastic Anemia
Pipeline by Development Stage
Drug Modality Breakdown
Hematology is a $3.6B market dominated by a single blockbuster (IMBRUVICA at 65% share) with moderate consolidation among 15 companies.
Key Trends
- IMBRUVICA monopoly creates revenue concentration risk but sustained peak-cycle performance
- Multiple patent cliffs 2027-2030 will drive significant biosimilar/generic competition
- 1,109 active trials signal robust pipeline activity in underexplored indications like myelofibrosis and platelet disorders
Career Verdict
Hematology offers solid commercial and medical affairs opportunities in a stable, high-margin market, but pipeline diversity remains limited outside oncology-adjacent BTK inhibitors.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | IMBRUVICA (ibrutinib) | AbbVie | $2.4B | 65% | Peak | Stable | 9.0yr |
| 2 | PROMACTA (eltrombopag olamine) | Novartis | $558M | 15% | LOE Approaching | Declining | 1.7yr |
| 3 | AURYXIA (ferric citrate) | Ipsen | $183M | 5% | Peak | Stable | 4.2yr |
| 4 | OXBRYTA (voxelotor) | Pfizer | $101M | 3% | Peak | Growing | 11.4yr |
| 5 | DOPTELET (avatrombopag maleate) | Unknown | $96M | 3% | LOE Approaching | Declining | 1.2yr |
Drug Class Breakdown
dominates market, stable
multiple players, patent risk
niche, CKD-focused
sickle cell focused, growing
myeloproliferative neoplasms, early growth
legacy class, biosimilar pressure
biosimilar-saturated, mature
Career Outlook
StableHematology is a stable, mature therapeutic area with predictable commercial demand but limited innovation upside. The market is defensible by IMBRUVICA (peak through 2035) and near-term patent cliff risks (2027-2030) will create managed-care and payer expertise needs. Long-term career growth depends on successful pipeline diversification beyond BTK inhibitors and late-stage pipeline expansion.
Breaking In
Enter via Clinical Operations or Medical Affairs to build hematology disease knowledge; specialize early in rare indications (ITP, myelofibrosis) where differentiation exists.
For Experienced Professionals
Experienced professionals should target Bristol Myers Squibb, Novartis, or GSK to lead patent-cliff transition strategies and next-generation mechanism adoption (JAK, TPO agonists).
In-Demand Skills
Best For
Hiring Landscape
Hematology hiring is concentrated in Commercial (24 roles, $201K avg) and Medical Affairs (15 roles, $204K avg) functions, reflecting a mature market focused on market penetration and specialist education. Labcorp, Bristol Myers Squibb, and Regeneron lead hiring, suggesting demand in diagnostics, R&D, and rare disease support. Notably low R&D hiring (7 roles, $147K avg) indicates limited pipeline-driven growth outside established players.
Top Hiring Companies
By Department
Commercial and Medical Affairs roles offer highest compensation and most openings; entry-level clinical operations salaries lag at $91K, while R&D roles are scarce and lower-paid.
On Market (2)
Approved therapies currently available
Competitive Landscape
15 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 33 trials with date data
Clinical Trials (34)
Total enrollment: 1,492 patients across 34 trials
A Study of Romiplostim for the Treatment of Refractory Transfusion-dependent NSAA
Ropustin for Refractory Aplastic Anaemia After Radiotherapy - a Single-centre, Prospective, Open-label, Single-arm Study
Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA
A Prospective Study on the Treatment of Recurrent/Refractory/Intolerable NSAA With Lusutrombopag
Luspatercept Plus CsA vs CsA for the Treatment of Newly Diagnosed Non-Transfusion-Dependent NSAA
CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly
A Prospective, Randomized, Controlled Study of rhTPO in Combination With Herombopag + CsA vs Herombopag + CsA for the Treatment of Primary TD-NSAA
Efficacy of IST Combined With TPO-RA in the Treatment of AA and Establishment of a Recurrence Prediction System
ATG Combined With Cyclophosphamide And Cord Blood Transfusion in Treating Patients With Severe Aplastic Anemia
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
A Study to Assess Efficacy and Safety of PF-06462700 in Japanese Participants With Aplastic Anemia
Efficacy and Safety of Hetrombopag in Non-severe Aplastic Anemia
Avatrombopag Usage in NSAA
CK0801 for Treatment of Aplastic Anemia
UI-Romi-02; Romiplostim Added to Standard of Care for Treatment Naive and Relapsed or Refractory Severe Aplastic Anemia
CsA+EPAG/HPAG+Romiplostim N01 in the Treatment of Newly-diagnosed SAA/TD-NSAA
CsA+EPAG/HPAG+Romiplostim N01 in Newly-diagnosed SAA/TD-NSAA
Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia
Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia
Efficacy and Safety of CsA+AVA in the Treatment of NSAA in the Elderly
Efficacy and Safety in Transfusion Independent Non-severe Aplastic Anemia
Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia Patients
Study Assessed the Safety and Efficacy of Eltrombopag in Chinese Refractory or Relapsed Severe Aplastic Anemia (SAA) Subjects.
Posaconazole Prophylaxis During ATG Treatment for hMDS/AA Patients
A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia
Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
Phase II Study of Bone Marrow Transplantation Using Related Donors in Patients With Aplastic Anemia
Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia
Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones
Alefacept in Patients With Relapsed/Refractory Aplastic Anemia
Expanded Access Use of Itacitinib to Treat a Single Patient With Aplastic Anemia
Revolade Tablets Specified Drug-use Survey
ATGAM General Investigation
Related Jobs in Hematology
Associate Director, Brand Manager Hematology, New Markets
Hematology Account Representative
Account Operations Manager - Southeast
Manager, Global Regulatory Operations
Senior Therapeutic Area Specialist, Hematology- Peoria, IL
Clinical Development Medical Director, Hematology
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.